top of page

September 2019 // Company

Updated: Nov 6, 2020

Synendos Therapeutics was selected for the Innosuisse core coaching programme and awarded with CHF 35’000. The aim is to receive support with developing the strategy, structuring the organisation and advance product development as well as legal advice on issues surrounding protecting intellectual property, concluding agreements or taxes.

Recent Posts

See All

January 2024 // Company & Communication

Synendos granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510. Synendos transitions to a clinical-stage biotech company developing innovative Endocanna

October 2022 // Company

Synendos Therapeutics has been awarded with the Innosuisse Certificate Synendos has been awarded the Innosuisse certificate by Innosuisse Innovation Council. The Innosuisse certificate reflects remark

September 2022 // Company & Communication

Synendos Therapeutics is ranked TOP 100 Swiss Startups 2022 We are honored to be listed for the second year in a row as one of the TOP 100 Swiss Startups 2022. A big thank you to our team, partners, c

bottom of page